Bangkok Genomics Innovation Public Company LimitedSET: BKGI🇹🇭 TH

MD&A · 2024

Overview of Operations

Overview of Operations

Operating Results Overview for the year 2024

Company Separate Financial Statements

The company reported a net profit of 50.31 million Baht, representing a net profit margin of 14.55%. Net profit grew significantly from the same period last year by 18.17 million Baht or 56.53%, mainly due to an increase in revenue from sales, which was the sale of laboratory equipment with monthly reagent orders. Coupled with better control of service costs and administrative expenses, this resulted in an increase in net profit margin to 14.55% from 12.99%.

Operating Results & Financial Condition

Operating Results & Profitability

Revenue Structure


The Company's revenue from operations for the year 2024 increased by 92.20 million Baht or 37.57% compared to the previous year. This was mainly due to the following reasons:

• Service Revenue Increased by 15.12 million Baht or 6.26% from reproductive health services. Increased by 27.22 million Baht or 13.14% due to the Company's collaboration with more infertility clinics this year, resulting in an increase in preimplantation genetic testing for aneuploidy (PGT-A) services. In addition, other screening revenue increased by 14.88 million baht or 795.72%, mainly due to the Company winning a bidding project with a government agency, which the Company recognized all revenue from the project in Q3/2024. However, revenue from infectious disease testing decreased by 22.58 million Baht or 98.99 million Baht, as the COVID-19 situation in the country has improved significantly since Q3/2023, resulting in a decrease in revenue.

• Sale Revenue Increased by 77.08 million Baht or 1,922.19% due to the Company's expansion into the laboratory equipment market with monthly reagent orders in 2024. In addition, there were sales of laboratory reagents for testing services within the laboratory and sales of laboratory materials and equipment to government and private agencies. In addition, the Company won several reagent bids with government agencies in 2024.

• Other income Increased by 6.33 million Baht or 324.62%, mainly due to the recognition of interest income from savings deposits and fixed deposits.


The Company's operating revenue in Q4/2024 increased by 41.21 million Baht or 75.53% compared to the previous year (YoY).

• Service revenue Increased by 5.47 million Baht or 10.15% for the same reason as service revenue in 2024.

• Sale Revenue Increased by 35.74 million Baht or 5,415.15% compared to the previous year. This was due to the recognition of revenue from 2 government bidding projects and 1 project from the sale of equipment to the private sector in Q4/2024.

• Other income Increased by 0.73 million Baht or 70.19%, mainly due to the recognition of interest income from savings deposits and fixed deposits.


The Company's operating revenue in Q4/2024 increased by 8.05 million Baht or 9.18% compared to Q3/2024 (QoQ). This was mainly due to an increase in revenue from sales of other products of 11.27 million Baht or 44.85% compared to the previous quarter. This was due to the recognition of revenue from 2 government projects and 1 project from the sale of equipment to the private sector in Q4/2024.


Gross Profit and Gross Profit Margin from Sales


The Company had a gross profit from sales for the year 2024 of 24.55 million Baht, representing a gross profit margin of 30.28%, an increase of 24.28 million Baht or 8,992.59% from the previous year. This was due to the Company's expansion into the laboratory equipment market with monthly reagent orders in 2024. In addition, there were sales of laboratory reagents for testing services within the laboratory and sales of laboratory materials and equipment to government and private agencies. In addition, the Company successfully managed its sales costs more efficiently.


The Company had a gross profit from sales in Q4/2024 of 11.91 million Baht, representing a gross profit margin of 32.72 million Baht, an increase of 11.70 million Baht or 5,571.43% from the same period last year. This was due to the Company's expansion into the laboratory equipment market with monthly reagent orders in 2024. In addition, there were sales of laboratory reagents for testing services within the laboratory and sales of laboratory materials and equipment to government and private agencies.


The Company had a gross profit from sales in Q4/2024 of 11.91 million baht, representing a gross profit margin of 32.72 million baht, an increase of 2.09 million baht or 21.28% from Q3/2024. This is because the Company sold reagents to government agencies in Q4/2024.


Gross Profit and Gross Profit Margin from Services


The Company had a gross profit from services for the year 2024 of 115.52 million Baht, representing a gross profit margin of 45.04%, a slight decrease of 0.27% from the previous year. This was mainly due to the launch of a new product for cancer screening service this year, which involves sending samples abroad, resulting in higher service costs. In addition, in 2023, the gross profit margin of COVID-19-related services was relatively high, and this revenue was no longer present in 2024.


The Company had a gross profit from services in Q4/2024 of 26.89 million Baht, representing a gross profit margin of 45.29%, an increase of 4.07 million Baht or 17.84% from the same period last year. This was due to the Company's management of service costs, which decreased due to the increased number of samples tested, resulting in lower reagent costs.


The Company had a gross profit from services in Q4/2024 of 26.89 million Baht, representing a gross profit margin of 45.29%, an increase of 0.85 million Baht or 3.26% from Q3/2024. This was due to the increase in the number of samples of new products in Q4/2024, resulting in lower testing costs.


Operating Expenses


The Company's operating expenses for the year 2024 were 97.18 million baht, representing 28.09% of operating revenue. This can be analyzed as follows:

• Selling expenses increased by 11.16 million Baht or 39.50%. This was mainly due to expenses on online media and public relations related to the Company's products and services to increase market awareness.

• Finance costs decreased by 0.28 million Baht or 17.07%. Due to the decrease in interest expenses on finance leases from land leases.


The Company's operating expenses in Q4/2024 increased by 10.21 million Baht or 58.58% from the same period last year. This was mainly due to an increase in administrative expenses. In 2024, the Company had higher research and development expenses to test products to be launched in the future, as well as higher website development expenses.


The Company's operating expenses in Q4/2024 increased by 2.66 million Baht or 10.60% from the previous quarter. Mainly due to

• Selling expenses Increased by 1.26 million Baht or 12.95% due to the Company's expenses on online media, public relations, booths related to the Company's products and services, and the hiring of additional sales personnel to support the launch of new services in 2025.

• Administrative expenses Increased by 1.39 million Baht or 9.32% due to research and development expenses in Q4/2024 to test services to be launched in the future.

Liquidity & Capital Adequacy

Key Financial Ratios

• Return on equity in 2024 decreased from 13.30 percent in the previous year to 12.98 percent. This was due to a 98.99 percent decrease in revenue from infectious disease testing services due to the easing of the COVID-19 situation. However, the company has seen a significant increase in revenue from fertility services from the expansion of preimplantation genetic testing for aneuploidy (PGT-A) services. Currently, the company has partnered with several leading infertility clinics. In addition, in 2024, the company expanded its sales of laboratory equipment and reagent ordering to more government and private agencies.

• Current ratio and quick ratio in 2024 increased from the previous year (the current ratio increased from 5.96 times to 11.27 times, quick ratio increased from 4.37 times to 6.39 times). This is a result of the increase in cash received from the IPO.

• Average collection period in 2024 increased from 47.36 days in the previous year to 56.22 days. This is because the company has started to expand its market in selling laboratory equipment with reagents to government agencies, which have a longer payment period than private agencies, resulting in an increase in the average collection period.

• Average sales period in 2024 decreased from 52.02 days in the previous year to 38.56 days. As the company has started to expand its market in selling laboratory equipment with reagents, which has received more interest from the market, resulting in a decrease in the average sales period.

• Average payment period in 2024 increased from 20.01 days in the previous year to 32.75 days. The company has increased bargaining power to extend the debt repayment period due to the increasing number of samples, resulting in a higher volume of orders.

• Total debt to equity ratio in 2024 decreased from 0.24 times in the previous year to 0.13 times. As the company has received funds from the IPO, coupled with the fact that the company only has operating liabilities and no loans from financial institutions.

Asset Management Capability

Assets


As of December 31, 2023 and December 31, 2024, the Company had total assets of 293.02 million Baht and 607.59 million Baht, respectively. increased from the same period of the previous year by 314.57 million Baht or 107.35 percent, mainly due to the increase in cash received from the initial public offering and trade receivables, in line with higher revenue from operations.


Debt Securities with Financial Ratio Requirements

Debt Securities with Financial Ratio Requirements Issued?

No

Factors That May Affect Financial Condition

Factors or Incidents That May Materially Affect Financial Condition

In 2024, the laboratory business continued to experience steady growth both domestically and internationally, driven by the increasing global emphasis on health and wellness. This rising awareness has led many sectors to prioritize health-related businesses, positioning the industry as part of a prominent mega trend with strong long-term growth potential. However, the Company still faces several key risks and significant events that may impact its financial position and operations, as outlined below:


• Regulatory Changes: The implementation or revision of laws and regulations related to safety standards, quality, and environmental requirements may require the Company to make additional investments to ensure compliance.

• Economic and Industry Conditions: Fluctuations in the overall economy or a slowdown in relevant industries could affect customer demand and hinder the Company’s growth rate.

• Raw Material and Equipment Costs: Volatility in the prices of chemicals, lab equipment, and scientific instruments may impact the Company’s cost structure and affect gross profit margins.

• Technological Advancements: Ongoing innovations and technological developments in the laboratory industry may necessitate further investment in tools and equipment to maintain the Company’s competitive edge.

• Human Resource Risk: A shortage of skilled specialists or turnover in key positions may affect operational efficiency and lead to increased human resource costs.

• Customer and Partner Relationships: A high dependence on key customers or major suppliers may pose a risk to revenue stability if there are changes in trade relationships or supplier policies.

• Liquidity and Capital Risk: Difficulties in cash flow management or limited access to additional funding sources may impact the Company’s ability to operate or expand its business.

• Unforeseen Events: External factors such as natural disasters, pandemics, or global crises could disrupt operations, increase production costs, and impair service delivery.

The Company recognizes these potential risks and closely monitors ongoing developments. It is committed to implementing robust risk management strategies and adapting its business plans to align with an ever-changing business environment, ensuring sustained competitiveness and long-term growth.

Contents